{"id":44639,"date":"2022-06-02T23:01:30","date_gmt":"2022-06-02T21:01:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/"},"modified":"2022-06-02T23:01:30","modified_gmt":"2022-06-02T21:01:30","slug":"nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/","title":{"rendered":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022"},"content":{"rendered":"<div>\n<p>PARIS &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/5\/LOGO_NANO_EXPANDING_LIFE.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg\"><\/a><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nanobiotix.com&amp;esheet=52738227&amp;newsitemid=20220602005859&amp;lan=en-US&amp;anchor=NANOBIOTIX&amp;index=1&amp;md5=72e64b8aca1365091ab81ddb226b8e93\" rel=\"nofollow noopener\" shape=\"rect\">NANOBIOTIX<\/a> (Euronext: NANO \u2013 NASDAQ: NBTX \u2013 the \u2018\u2018<b>Company<\/b>\u2019\u2019)<b>,<\/b> a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022 at 9.30 AM Central European Time (CET), 3.30 AM Eastern Standard Time (EST), in the Company\u2019s offices at 60 Rue de Wattignies (5<sup>th<\/sup> Floor) 75012 Paris, France.\n<\/p>\n<p>\nThe notice of meeting, including the agenda, the draft detailed resolutions, and the principal details for attending and voting at this Ordinary and Extraordinary Annual Meeting of Shareholders were published in the French official bulletin of legal notices, the Bulletin des Annonces L\u00e9gales Obligatoires (BALO), on May 18, 2022<sup>1<\/sup>.\n<\/p>\n<p>\nThe documents and information concerning this shareholders\u2019 meeting are available to shareholders as provided by applicable law and regulations on the Company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.nanobiotix.com%2Fannual-general-meetings&amp;esheet=52738227&amp;newsitemid=20220602005859&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.nanobiotix.com%2Fannual-general-meetings&amp;index=2&amp;md5=648a3f14b084cd2a914b03191a575d3d\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/ir.nanobiotix.com\/annual-general-meetings<\/a>, at the Company\u2019s registered office, or upon request via email at <a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#105;&#110;&#x76;&#x65;&#x73;&#x74;&#x6f;&#x72;&#x73;&#64;nan&#111;&#98;&#105;&#111;&#116;&#x69;&#x78;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">i&#110;&#118;&#x65;&#x73;&#x74;&#x6f;r&#115;&#64;&#110;&#x61;&#x6e;&#x6f;bi&#111;&#116;&#x69;&#x78;&#x2e;co&#109;<\/a>.\n<\/p>\n<p>\nShareholders are kindly advised to consult the Company&#8217;s website on a regular basis, as it could be updated to specify the final terms and modalities of participation in this shareholders\u2019 meeting in accordance with sanitary, legal, or regulatory requirements.\n<\/p>\n<p>\n<b>2022 Financial Agenda<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nJune 23, 2022 \u2013 Annual General Meeting, Paris, France\n<\/li>\n<li>\nSeptember 28, 2022 \u2013 2022 Half-Year Corporate and Financial Update\n<\/li>\n<li>\nNovember 9, 2022 \u2013 Third Quarter 2022 Corporate and Financial Update\n<\/li>\n<\/ul>\n<p>\n<b>About NBTXR3<\/b>\n<\/p>\n<p>\nNBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate\u2019s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.\n<\/p>\n<p>\n<b>About NANOBIOTIX<\/b>\n<\/p>\n<p>\nNanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.\n<\/p>\n<p>\nFor more information about Nanobiotix, visit us at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nanobiotix.com&amp;esheet=52738227&amp;newsitemid=20220602005859&amp;lan=en-US&amp;anchor=www.nanobiotix.com&amp;index=3&amp;md5=0a8eea8c928e7d8f0e2373ad7920c8ee\" rel=\"nofollow noopener\" shape=\"rect\">www.nanobiotix.com<\/a> or follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnanobiotix&amp;esheet=52738227&amp;newsitemid=20220602005859&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=5de75e221f66c3453dad2fa2ae0a96bb\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2Fnanobiotix&amp;esheet=52738227&amp;newsitemid=20220602005859&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=cac054fca770b624c9cab185e51d0083\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.\n<\/p>\n<p>\n_______________________<br \/>\n<br \/><sup>1<\/sup> For the purposes of specificity, the agenda published on the Company\u2019s website includes an added draft resolution(n\u00b037), which will be reflected in the updated agenda to be published in the BALO by June 8, 2022.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<i>Nanobiotix<\/i><br \/><b>Communications Department<\/b><br \/><i>Brandon Owens<\/i><br \/><i>VP, Communications<\/i><br \/>+1 (617) 852-4835<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x63;&#111;&#110;&#116;&#97;&#99;&#116;&#64;nano&#x62;&#x69;&#x6f;&#x74;&#x69;&#x78;&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">co&#110;&#116;&#x61;&#x63;&#x74;&#x40;na&#110;&#111;&#x62;&#x69;&#x6f;&#x74;ix&#46;&#99;&#111;&#x6d;<\/a>\n<\/p>\n<p>\n<b>Investor Relations Department<\/b><br \/><i>Kate McNeil<\/i><br \/><i>SVP, Investor Relations<\/i><br \/>+1 (609) 678-7388<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;&#x6c;&#x74;&#111;&#58;&#x69;&#x6e;&#118;&#101;&#x73;&#x74;&#111;&#114;&#x73;&#x40;&#110;&#97;&#x6e;&#x6f;&#98;&#105;&#x6f;&#x74;&#105;&#120;&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#118;&#101;st&#x6f;&#x72;&#x73;&#64;na&#x6e;&#x6f;&#x62;&#105;&#111;t&#x69;&#x78;&#x2e;&#99;&#111;m<\/a>\n<\/p>\n<p>\n<i>Media Relations<\/i><br \/>FR \u2013 <b>Ulysse Communication<\/b><br \/>Pierre-Louis Germain<br \/>\n<br \/>+33 (0) 6 64 79 97 51<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x70;l&#x67;e&#x72;m&#x61;i&#110;&#x40;&#117;&#x6c;&#121;&#x73;&#115;&#x65;&#45;&#x63;o&#x6d;m&#x75;n&#x69;c&#97;&#x74;&#105;&#x6f;&#110;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#108;&#103;e&#x72;&#x6d;&#97;i&#x6e;&#x40;&#117;l&#x79;&#x73;&#115;e&#x2d;&#x63;&#111;m&#x6d;&#x75;&#110;i&#x63;&#x61;&#116;&#105;o&#x6e;&#x2e;&#99;o&#x6d;<\/a>\n<\/p>\n<p>\nUS \u2013 <b>Porter Novelli<\/b><br \/>Caitlin Hunt<br \/>\n<br \/>+1 (781) 985-5967<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x43;&#x61;&#x69;&#x74;&#108;&#105;&#110;&#46;&#104;&#117;&#110;t&#64;port&#x65;&#x72;&#x6e;&#x6f;&#x76;&#x65;&#x6c;&#x6c;&#x69;&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#67;&#x61;&#105;&#x74;&#108;&#x69;&#110;&#x2e;&#104;&#x75;&#110;&#x74;&#64;&#x70;o&#x72;t&#x65;r&#x6e;o&#x76;e&#108;&#x6c;&#105;&#x2e;&#99;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PARIS &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Regulatory News: NANOBIOTIX (Euronext: NANO \u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022 at 9.30 AM Central European Time (CET), 3.30 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44639","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PARIS &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Regulatory News: NANOBIOTIX (Euronext: NANO \u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022 at 9.30 AM Central European Time (CET), 3.30 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-02T21:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022\",\"datePublished\":\"2022-06-02T21:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/\"},\"wordCount\":497,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005859\\\/en\\\/744572\\\/21\\\/LOGO_NANO_EXPANDING_LIFE.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/\",\"name\":\"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005859\\\/en\\\/744572\\\/21\\\/LOGO_NANO_EXPANDING_LIFE.jpg\",\"datePublished\":\"2022-06-02T21:01:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005859\\\/en\\\/744572\\\/21\\\/LOGO_NANO_EXPANDING_LIFE.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220602005859\\\/en\\\/744572\\\/21\\\/LOGO_NANO_EXPANDING_LIFE.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/","og_locale":"en_US","og_type":"article","og_title":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend","og_description":"PARIS &amp; CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Regulatory News: NANOBIOTIX (Euronext: NANO \u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022 at 9.30 AM Central European Time (CET), 3.30 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-02T21:01:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022","datePublished":"2022-06-02T21:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/"},"wordCount":497,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/","url":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/","name":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg","datePublished":"2022-06-02T21:01:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220602005859\/en\/744572\/21\/LOGO_NANO_EXPANDING_LIFE.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-annual-shareholders-general-meeting-to-be-held-on-june-23-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NANOBIOTIX Annual Shareholders\u2019 General Meeting to Be Held on June 23, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44639"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44639\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}